Starting the conversation: CRISPR's role in India.

Clicks: 322
ID: 12818
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #5 of 8 articles by views in indian journal of medical ethics

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
The applications of gene editing technologies such as CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) have grown significantly in recent years. Several countries have adopted different stances on the regulation of such technology; however, India does not have any legally enforceable regulations in place. There is a need for such a development as India's regulatory, sociocultural, and economic landscape is unique. First, we discuss the uncertainty regarding India's regulatory capacity to enforce ethical standards for CRISPR use. Then, we discuss unique driving forces that could lead to the misuse of CRISPR in India, such as certain sociocultural norms like preferences for fair skin and public demand for sex determination. Given these previous concerns, we posit the question; where on the priority list does CRISPR stand in the context of public health in India?
Reference Key
udwadia2019startingindian Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Udwadia, Farhad;Singh, Shivam;
Journal indian journal of medical ethics
Year 2019
DOI
10.20529/IJME.2019.016
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.